Exhibit 99.1 Corporate Overview September 2020 1Exhibit 99.1 Corporate Overview September 2020 1


Forward Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words anticipate , believe , could , estimate , expect , intend , may , plan , predict , project , will and similar terms and phrases may be used to identify forward-looking statements in this presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. These forward-looking statements are subject to risks and uncertainties including, among other things, the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, our ability to maintain regulatory approval for ANJESO®, our ability to successfully commercialize ANJESO®; the extent to which government reimbursement for ANJESO remains available at adequate levels and the impact of any changes in government reimbursement on our pricing of ANJESO; the acceptance of ANJESO® by the medical community, including physicians, patients, health care providers and hospital formularies; our ability and that of our third party manufacturers to successfully scale-up our commercial manufacturing process for ANJESO®, our ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO®, our ability to raise future financing for continued product development and ANJESO® commercialization, our ability to manage costs and execute on our operational and budget plans, the accuracy of our estimates of the potential market for ANJESO®, our ability to achieve our financial goals; and our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward- looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law. This presentation is intended to be non-promotional and for investor discussion purposes only. 2 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comForward Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words anticipate , believe , could , estimate , expect , intend , may , plan , predict , project , will and similar terms and phrases may be used to identify forward-looking statements in this presentation. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. These forward-looking statements are subject to risks and uncertainties including, among other things, the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, our ability to maintain regulatory approval for ANJESO®, our ability to successfully commercialize ANJESO®; the extent to which government reimbursement for ANJESO remains available at adequate levels and the impact of any changes in government reimbursement on our pricing of ANJESO; the acceptance of ANJESO® by the medical community, including physicians, patients, health care providers and hospital formularies; our ability and that of our third party manufacturers to successfully scale-up our commercial manufacturing process for ANJESO®, our ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO®, our ability to raise future financing for continued product development and ANJESO® commercialization, our ability to manage costs and execute on our operational and budget plans, the accuracy of our estimates of the potential market for ANJESO®, our ability to achieve our financial goals; and our ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward- looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law. This presentation is intended to be non-promotional and for investor discussion purposes only. 2 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Company Highlights • ANJESO® (meloxicam) injection* – Product launched June 2020 – Approved February 20, 2020 for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics – Significant Potential Commercial Opportunity • Additional pipeline candidates in clinical stage development for acute care settings • Baudax Cash position – $39.4 million as of June 30, 2020 – $50 million credit facility secured in May 2020; $10 million drawn – Short dated Cash Exercisable Series B Warrants expected to provide additional $25 million in gross proceeds before or by April 2021, assuming full exercise. As of June 30, 2020, warrant exercises have provided $2.5 million in net proceeds. • Experienced management team with significant commercial, development, and regulatory experience * Limitation of Use: Because of delayed onset of analgesia, ANJESO® alone is not recommended for use when rapid onset of analgesia is required. 3 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comCompany Highlights • ANJESO® (meloxicam) injection* – Product launched June 2020 – Approved February 20, 2020 for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics – Significant Potential Commercial Opportunity • Additional pipeline candidates in clinical stage development for acute care settings • Baudax Cash position – $39.4 million as of June 30, 2020 – $50 million credit facility secured in May 2020; $10 million drawn – Short dated Cash Exercisable Series B Warrants expected to provide additional $25 million in gross proceeds before or by April 2021, assuming full exercise. As of June 30, 2020, warrant exercises have provided $2.5 million in net proceeds. • Experienced management team with significant commercial, development, and regulatory experience * Limitation of Use: Because of delayed onset of analgesia, ANJESO® alone is not recommended for use when rapid onset of analgesia is required. 3 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Experienced Management & Launch Leadership Team Gerri Henwood – President and CEO Founded Recro Pharma (REPH), Auxilium Pharmaceuticals (AUXL – NASDAQ then Endo) and IBAH (NASDAQ then Omnicare); GSK Ryan Lake – Chief Financial Officer John Harlow – EVP and Chief Commercial Officer 20 years of senior financial and life sciences leadership Over 20 years commercial launch and leadership experience – experience – Recro Pharma (REPH), Aspire Bariatrics, DSM Recro, Novartis, Alpharma/King/Pfizer, Endo, Shionogi, Janssen (DSM.AS) - DSM Biomedical, Kensey Nash (KNSY), Deloitte Greg Gangemi – Vice President, Sales, Trade & Market Access Stewart McCallum, MD – Chief Medical Officer Over 25 years of industry, launch and operations experience – Board certified Urologist (Stanford & Weill Cornell) with 13 years Recro, Sepracor/Sunovion, Cubist, Ferring and Ocular of industry experience at Recro Pharma and GSK Therapeutix Jyrki Mattila, M.D., Ph.D – EVP, Business Development Janeese Carter – Senior Director, Marketing Over 30 years of BD and general management experience – Over 15 years of marketing, market research, new business Recro, Lipocine, iCeutica, LZ Therapeutics, Auxilium & Orion strategy, and sales – Recro Pharma, CSL Behring, Pfizer/Wyeth Paul Baddeley – Senior Director, Commercial Operations 20 years of industry and consulting experience in commercial operations & analytics – Recro, Collegium, IMS Health, Endo 4Experienced Management & Launch Leadership Team Gerri Henwood – President and CEO Founded Recro Pharma (REPH), Auxilium Pharmaceuticals (AUXL – NASDAQ then Endo) and IBAH (NASDAQ then Omnicare); GSK Ryan Lake – Chief Financial Officer John Harlow – EVP and Chief Commercial Officer 20 years of senior financial and life sciences leadership Over 20 years commercial launch and leadership experience – experience – Recro Pharma (REPH), Aspire Bariatrics, DSM Recro, Novartis, Alpharma/King/Pfizer, Endo, Shionogi, Janssen (DSM.AS) - DSM Biomedical, Kensey Nash (KNSY), Deloitte Greg Gangemi – Vice President, Sales, Trade & Market Access Stewart McCallum, MD – Chief Medical Officer Over 25 years of industry, launch and operations experience – Board certified Urologist (Stanford & Weill Cornell) with 13 years Recro, Sepracor/Sunovion, Cubist, Ferring and Ocular of industry experience at Recro Pharma and GSK Therapeutix Jyrki Mattila, M.D., Ph.D – EVP, Business Development Janeese Carter – Senior Director, Marketing Over 30 years of BD and general management experience – Over 15 years of marketing, market research, new business Recro, Lipocine, iCeutica, LZ Therapeutics, Auxilium & Orion strategy, and sales – Recro Pharma, CSL Behring, Pfizer/Wyeth Paul Baddeley – Senior Director, Commercial Operations 20 years of industry and consulting experience in commercial operations & analytics – Recro, Collegium, IMS Health, Endo 4


Highlights 5Highlights 5


ANJESO® (meloxicam) injection Overview • Proprietary non-opioid, long-acting IV form – Incorporates Alkermes’ NanoCrystal® technology • Once daily, long-acting, preferential COX-2 inhibitor for moderate to severe acute pain • Commercial Launch Underway – Receipt of permanent J-code effective October 1, 2020 and it is expected to replace the previously issued C-code that became effective July 1, 2020 – Signed contracts with a top 3 IDN and multiple GPOs; others in-process • Orange Book Listed patents run until 2030 6 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® (meloxicam) injection Overview • Proprietary non-opioid, long-acting IV form – Incorporates Alkermes’ NanoCrystal® technology • Once daily, long-acting, preferential COX-2 inhibitor for moderate to severe acute pain • Commercial Launch Underway – Receipt of permanent J-code effective October 1, 2020 and it is expected to replace the previously issued C-code that became effective July 1, 2020 – Signed contracts with a top 3 IDN and multiple GPOs; others in-process • Orange Book Listed patents run until 2030 6 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Demonstrated COX-2 Preferential Once-daily IV Up to 24-hour Safety & Tolerability IV NSAID* push pain relief Efficacy in That can be Ready-to-use, no Evaluated in more orthopedic & soft incorporated into reconstitution or 1 than 1400 patients tissue procedures MMA protocols refrigeration 1. Data on file. Baudax Bio, Inc. *The mechanism of action of IV meloxicam, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-1 = cyclooxygenase 1; COX-2 = cyclooxygenase 2; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; MMA = multimodal analgesia 7 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Demonstrated COX-2 Preferential Once-daily IV Up to 24-hour Safety & Tolerability IV NSAID* push pain relief Efficacy in That can be Ready-to-use, no Evaluated in more orthopedic & soft incorporated into reconstitution or 1 than 1400 patients tissue procedures MMA protocols refrigeration 1. Data on file. Baudax Bio, Inc. *The mechanism of action of IV meloxicam, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-1 = cyclooxygenase 1; COX-2 = cyclooxygenase 2; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; MMA = multimodal analgesia 7 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® Evaluated in Three Phase 3 Studies ANJESO 30 a Study Population Placebo Primary Endpoint Outcome mg 31% greater pain reduction vs 1 Bunionectomy n=100 n=101 SPID48* placebo (p=0.0034) 17% greater pain reduction vs 2 Abdominoplasty n=110 n=109 SPID24* placebo (p=0.0145) Safety, including number of Safety study; multiple hard patients with adverse Adverse Events comparable to n=538 n=183 3 & soft tissue procedures events up to 28 days after placebo dosing *SPID (Sum of Pain Intensity Differences) is calculated by the sum of the difference between current pain and baseline pain at each post-dose time point. SPID48 = summed pain intensity difference from 0-48 hours, SPID24 = a summed pain intensity difference from 0-24 hours. All studies completed with efficacy, safety and opioid reduction data. 1. Pollak RA et al. Clin J Pain. 2018;34(10):918-926. 2. Singla N et al. Plast Reconstr Surg Glob Open. 2018;6:e1846. 3. Bergese SD et al. Clin Pharmacol Drug Dev. 2019;8(8) 1062-1072. 8 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® Evaluated in Three Phase 3 Studies ANJESO 30 a Study Population Placebo Primary Endpoint Outcome mg 31% greater pain reduction vs 1 Bunionectomy n=100 n=101 SPID48* placebo (p=0.0034) 17% greater pain reduction vs 2 Abdominoplasty n=110 n=109 SPID24* placebo (p=0.0145) Safety, including number of Safety study; multiple hard patients with adverse Adverse Events comparable to n=538 n=183 3 & soft tissue procedures events up to 28 days after placebo dosing *SPID (Sum of Pain Intensity Differences) is calculated by the sum of the difference between current pain and baseline pain at each post-dose time point. SPID48 = summed pain intensity difference from 0-48 hours, SPID24 = a summed pain intensity difference from 0-24 hours. All studies completed with efficacy, safety and opioid reduction data. 1. Pollak RA et al. Clin J Pain. 2018;34(10):918-926. 2. Singla N et al. Plast Reconstr Surg Glob Open. 2018;6:e1846. 3. Bergese SD et al. Clin Pharmacol Drug Dev. 2019;8(8) 1062-1072. 8 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® Adverse Events Across All Phase 3 Studies Adverse Reactions in Placebo-Controlled Phase 3 ANJESO 30 mg Placebo Clinical Trials occurring in ≥2% of Patients Treated (n=748) (n=393) with ANJESO® and at a greater frequency than Placebo % (n) % (n) Constipation 57 (7.6%) 24 (6.1%) Gamma-Glutamyl Transferase Increased 21 (2.8%) 6 (1.5%) ANJESO (n=748) Anemia 18 (2.4%) 4 (1.0%) Source: ANJESO Prescribing Information 9 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® Adverse Events Across All Phase 3 Studies Adverse Reactions in Placebo-Controlled Phase 3 ANJESO 30 mg Placebo Clinical Trials occurring in ≥2% of Patients Treated (n=748) (n=393) with ANJESO® and at a greater frequency than Placebo % (n) % (n) Constipation 57 (7.6%) 24 (6.1%) Gamma-Glutamyl Transferase Increased 21 (2.8%) 6 (1.5%) ANJESO (n=748) Anemia 18 (2.4%) 4 (1.0%) Source: ANJESO Prescribing Information 9 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Two Phase 3b Health Economic Studies Completed with Preoperative Administration of ANJESO® Selection of ANJESO® Primary 1 2 Study Population Placebo Secondary Selection of Results 30 mg Endpoint Endpoints Evaluate efficacy of Preoperative administration of Evaluate impact on Total Knee preoperative* ANJESO as part of a MMA regimen was pain control and Arthroplasty n=93 n=88 administration associated with lower total mean hospital costs healthcare resource (TKA) measured by total >$2,500 during the hospital stay than patients in utilization opioid consumption the placebo group Evaluate impact on Evaluate safety and Preoperative administration of hospital LOS, opioid Bowel tolerability of ANJESO as part of a MMA regimen was well Resection n=27 n=28 consumption and preoperative* tolerated and decreased mean LOS by 1.1 days Surgery healthcare resource administration (3.6 vs 4.7 days) utilization *Preoperative dosing = ANJESO 30mg was administered prior to surgical incision (TKA) or 30 minutes prior to the start of surgery (bowel resection), then once-daily while in hospital until discharge or IV analgesic was no longer appropriate. 1. Studies completed with efficacy, safety, opioid reduction and healthcare resource utilization measures. 2. Data on file. Baudax Bio, Inc. Abstracts and publications pending. MMA = multimodal analgesia; LOS = length of stay 10 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comTwo Phase 3b Health Economic Studies Completed with Preoperative Administration of ANJESO® Selection of ANJESO® Primary 1 2 Study Population Placebo Secondary Selection of Results 30 mg Endpoint Endpoints Evaluate efficacy of Preoperative administration of Evaluate impact on Total Knee preoperative* ANJESO as part of a MMA regimen was pain control and Arthroplasty n=93 n=88 administration associated with lower total mean hospital costs healthcare resource (TKA) measured by total >$2,500 during the hospital stay than patients in utilization opioid consumption the placebo group Evaluate impact on Evaluate safety and Preoperative administration of hospital LOS, opioid Bowel tolerability of ANJESO as part of a MMA regimen was well Resection n=27 n=28 consumption and preoperative* tolerated and decreased mean LOS by 1.1 days Surgery healthcare resource administration (3.6 vs 4.7 days) utilization *Preoperative dosing = ANJESO 30mg was administered prior to surgical incision (TKA) or 30 minutes prior to the start of surgery (bowel resection), then once-daily while in hospital until discharge or IV analgesic was no longer appropriate. 1. Studies completed with efficacy, safety, opioid reduction and healthcare resource utilization measures. 2. Data on file. Baudax Bio, Inc. Abstracts and publications pending. MMA = multimodal analgesia; LOS = length of stay 10 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Dosing and Administration Highlights • Once-daily, IV bolus injection push over 15 seconds • Administered as a 30-mg (1 mL) • Available as a small* (2 mL) single dose vial • Ready-to-use • No reconstitution required • Room temperature storage – no need to refrigerate When initiating ANJESO, monitor patient analgesic response. Because the median time to meaningful pain relief was 2 and 3 hours after ANJESO administration in two clinical studies, a non-NSAID analgesic with a rapid onset of effect may be needed, for example, upon anesthetic emergence or resolution of local or regional anesthetic blocks. Source: ANJESO Prescribing Information. Some patients may not experience adequate analgesia for the entire 24-hour dosing interval and may require administration of a *Vial size approximately 16 X 34.5 mm short-acting, non-NSAID, immediate-release analgesic. 11 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Dosing and Administration Highlights • Once-daily, IV bolus injection push over 15 seconds • Administered as a 30-mg (1 mL) • Available as a small* (2 mL) single dose vial • Ready-to-use • No reconstitution required • Room temperature storage – no need to refrigerate When initiating ANJESO, monitor patient analgesic response. Because the median time to meaningful pain relief was 2 and 3 hours after ANJESO administration in two clinical studies, a non-NSAID analgesic with a rapid onset of effect may be needed, for example, upon anesthetic emergence or resolution of local or regional anesthetic blocks. Source: ANJESO Prescribing Information. Some patients may not experience adequate analgesia for the entire 24-hour dosing interval and may require administration of a *Vial size approximately 16 X 34.5 mm short-acting, non-NSAID, immediate-release analgesic. 11 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Commercial Opportunity 12Commercial Opportunity 12


Large Opportunity Waiting For Non-Opioid Solutions: Market Can Be Targeted Efficiently & Effectively HOSPITAL INPATIENT HOPD ASC TOTAL ADDRESSABLE 11m 9m 2.2m ~22m Procedures PROCEDURES* Orthopedic (Hip/Knee, Spine, other) General Surgery CORE TARGET PROCEDURES Colorectal TARGETED 3.4m 6.9m 1.0m ~11.3m Procedures PROCEDURES TARGETED ~1,450 HOSPITALS ~550 ASCs ~2,000 Accounts ACCOUNTS Source: Definitive, LexisNexis and Company Estimates. *Includes addressable procedures where ANJESO use is anticipated. 13 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comLarge Opportunity Waiting For Non-Opioid Solutions: Market Can Be Targeted Efficiently & Effectively HOSPITAL INPATIENT HOPD ASC TOTAL ADDRESSABLE 11m 9m 2.2m ~22m Procedures PROCEDURES* Orthopedic (Hip/Knee, Spine, other) General Surgery CORE TARGET PROCEDURES Colorectal TARGETED 3.4m 6.9m 1.0m ~11.3m Procedures PROCEDURES TARGETED ~1,450 HOSPITALS ~550 ASCs ~2,000 Accounts ACCOUNTS Source: Definitive, LexisNexis and Company Estimates. *Includes addressable procedures where ANJESO use is anticipated. 13 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® Stated Shares in Market Surveys Remain Consistently Positive Approximately 65% of MDs surveyed believe they would likely use ANJESO with stated procedure shares ranging from 39-52% Anticipated Change in Share in PACU Setting ANJESO Stated Share by Procedure Type – 1 2 % of Surgeries % of Patients Oral Opioids Knee & Shoulder Arthroscopy 46% -6% Fentanyl Total Hip Replacement 45% -6% IV Opioids Total Knee Replacement -13% 47% IV Ketorolac Other Orthopedic Procedures -7% 40% IV Ibuprofen Hernia Repair -1% 52% IV Acetaminophen Laproscopic Cholesysectomy -3% 48% Local Injections Soft Tissue Procedures 0% 39% Bowel Resection and Other ANJESO26% 44% Colorectal Procedures *Product profile in surveys was fair balanced, based on clinical data and similar to final label. Stated shares do not account for possible access restrictions (i.e. special order, quantity limits, specific procedural prescribing, limitations by site of care, etc.) 1. December 2017 – Blinded, Third Party Market Research, n=462. 2. January 2020 – Blinded, Third Party Market Research, n=400. PACU = Post-Anesthesia Care Unit 14 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® Stated Shares in Market Surveys Remain Consistently Positive Approximately 65% of MDs surveyed believe they would likely use ANJESO with stated procedure shares ranging from 39-52% Anticipated Change in Share in PACU Setting ANJESO Stated Share by Procedure Type – 1 2 % of Surgeries % of Patients Oral Opioids Knee & Shoulder Arthroscopy 46% -6% Fentanyl Total Hip Replacement 45% -6% IV Opioids Total Knee Replacement -13% 47% IV Ketorolac Other Orthopedic Procedures -7% 40% IV Ibuprofen Hernia Repair -1% 52% IV Acetaminophen Laproscopic Cholesysectomy -3% 48% Local Injections Soft Tissue Procedures 0% 39% Bowel Resection and Other ANJESO26% 44% Colorectal Procedures *Product profile in surveys was fair balanced, based on clinical data and similar to final label. Stated shares do not account for possible access restrictions (i.e. special order, quantity limits, specific procedural prescribing, limitations by site of care, etc.) 1. December 2017 – Blinded, Third Party Market Research, n=462. 2. January 2020 – Blinded, Third Party Market Research, n=400. PACU = Post-Anesthesia Care Unit 14 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Commercial Launch 15Commercial Launch 15


Early Progress Promising on Pull Through Opportunities WHOLESALERS GOVERNMENT FILINGS GPOs STRATEGIC CUSTOMERS ANJESO STOCKED IN SECURING ACCESS TO 95% OF HOSPITALS KEY CUSTOMERS MAJOR WHOLESALERS GOV’T PROGAMS ARE GPO MEMBERS HAVE INTEREST • Two GPO agreements • Wholesaler and Specialty • Pass through status & signed and effective in July • Large national agreement Distributors agreements in C-code effective 7/1/2020 and August went effective 7/1 and place with sufficient launch • CMS granted permanent • Additional GPO agreements sales team focused on under review and inventory in forward J-code (HCPCS) to become regional pull-through distribution centers evaluation effective 10/1/2020 process • VHA Interim and FSS • Team focused on driving contracts in place providing awareness and early usage at targeted accounts access to VA/DOD, Tricare, Medicare, FSS and 340b 16 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comEarly Progress Promising on Pull Through Opportunities WHOLESALERS GOVERNMENT FILINGS GPOs STRATEGIC CUSTOMERS ANJESO STOCKED IN SECURING ACCESS TO 95% OF HOSPITALS KEY CUSTOMERS MAJOR WHOLESALERS GOV’T PROGAMS ARE GPO MEMBERS HAVE INTEREST • Two GPO agreements • Wholesaler and Specialty • Pass through status & signed and effective in July • Large national agreement Distributors agreements in C-code effective 7/1/2020 and August went effective 7/1 and place with sufficient launch • CMS granted permanent • Additional GPO agreements sales team focused on under review and inventory in forward J-code (HCPCS) to become regional pull-through distribution centers evaluation effective 10/1/2020 process • VHA Interim and FSS • Team focused on driving contracts in place providing awareness and early usage at targeted accounts access to VA/DOD, Tricare, Medicare, FSS and 340b 16 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Field Engaging Customers In-Person & Virtually with Comprehensive Resources • Core Visual Aid • Phase 3 Publication Flashcard • Promotional Leave Behind • Phase 3 Abdominoplasty Reprint • Rep Inservice Deck • Phase 3 Bunionectomy Reprint • Tabletop Panels • Phase 3 Safety Study Reprint • Baudax Bio Brochure • Pharmacoeconomic Materials Detail Aids & Publication Collateral Resources • Site specific billing resources Market Access/ Speaker Program • Comprehensive Billing Guides • Virtual and In- Reimbursement • NDC Announcements Personal Speaker • HUB flashcard Programs • Coverage Announcements • Commercial Claim Forms 17 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comField Engaging Customers In-Person & Virtually with Comprehensive Resources • Core Visual Aid • Phase 3 Publication Flashcard • Promotional Leave Behind • Phase 3 Abdominoplasty Reprint • Rep Inservice Deck • Phase 3 Bunionectomy Reprint • Tabletop Panels • Phase 3 Safety Study Reprint • Baudax Bio Brochure • Pharmacoeconomic Materials Detail Aids & Publication Collateral Resources • Site specific billing resources Market Access/ Speaker Program • Comprehensive Billing Guides • Virtual and In- Reimbursement • NDC Announcements Personal Speaker • HUB flashcard Programs • Coverage Announcements • Commercial Claim Forms 17 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Prepared for an Efficient Launch Efficient Launch Solid Foundation Total Accounts: Surgical claims data identified ~2,000 accounts 1450 Hospitals & 550 ASCs that cover 80% of the market Launch Targets: 800 – 1000 Accounts Launching with ~50 Reps enables coverage of 800- 1,000 accounts (~50% of market) High Priority Targets: ~200 Hospitals Prior field team activity qualified and prioritized & ~100 ASCs ~300 accounts Source: Definitive, LexisNexis and Company Estimates. *Includes addressable procedures where ANJESO use is anticipated. 18 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comPrepared for an Efficient Launch Efficient Launch Solid Foundation Total Accounts: Surgical claims data identified ~2,000 accounts 1450 Hospitals & 550 ASCs that cover 80% of the market Launch Targets: 800 – 1000 Accounts Launching with ~50 Reps enables coverage of 800- 1,000 accounts (~50% of market) High Priority Targets: ~200 Hospitals Prior field team activity qualified and prioritized & ~100 ASCs ~300 accounts Source: Definitive, LexisNexis and Company Estimates. *Includes addressable procedures where ANJESO use is anticipated. 18 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Wholesale Acquisition Cost: ANJESO and Other Non-Opioids $94.00 $94.74 $9.84 $47.37 $78.60 $142.11 $173.84 $334.18 IV Ketorolac Ofirmev Caldolor Ofirmev Ofirmev Ofirmev Exparel (per day) (per dose) (4X dose) (2X dose) (3X dose) (4X dose) (per dose) Note: For illustration only. Not drawn to scale § Economic Analysis of two Phase 3b studies completed with positive data available Strong Economic Evidence Available at § Budget Impact & Cost Effectiveness Models to address ANJESO cost effectiveness vs. other IV analgesics Launch § Retrospective Analyses of claims database that models real-world AE rates and costs Source: Wholesale Acquisition Cost Prices from Red Book accessed August 2020, which may not represent a customer’s cost. Price per day equals dosing schedule times price per dose. Dosing schedule according to product prescribing information for 24-hour coverage. Generic ketorolac has multiple manufacturers, price reflects the lowest manufacturer WAC. 19 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comWholesale Acquisition Cost: ANJESO and Other Non-Opioids $94.00 $94.74 $9.84 $47.37 $78.60 $142.11 $173.84 $334.18 IV Ketorolac Ofirmev Caldolor Ofirmev Ofirmev Ofirmev Exparel (per day) (per dose) (4X dose) (2X dose) (3X dose) (4X dose) (per dose) Note: For illustration only. Not drawn to scale § Economic Analysis of two Phase 3b studies completed with positive data available Strong Economic Evidence Available at § Budget Impact & Cost Effectiveness Models to address ANJESO cost effectiveness vs. other IV analgesics Launch § Retrospective Analyses of claims database that models real-world AE rates and costs Source: Wholesale Acquisition Cost Prices from Red Book accessed August 2020, which may not represent a customer’s cost. Price per day equals dosing schedule times price per dose. Dosing schedule according to product prescribing information for 24-hour coverage. Generic ketorolac has multiple manufacturers, price reflects the lowest manufacturer WAC. 19 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Surgical Setting Coding and Reimbursement Hospital Inpatient Hospital Outpatient Ambulatory Surgery Centers M Me ed diic ca ar re e M Me ed diic ca ar re e M Me ed diic ca ar re e •• U Us se e J J3 34 49 90 0•• U Un niiq qu ue e C Co od de e, , C C9 90 05 59 9 •• U Un niiq qu ue e C Co od de e, , C C9 90 05 59 9 •• R Re eiim mb bu ur rs se em me en nt t b bu un nd dlle ed d iin nt to o ( (IIn nj je ec ct tiio on n, , M Me ello ox xiic ca am m 1 1m mg g) ) ( (IIn nj je ec ct tiio on n, , M Me ello ox xiic ca am m 1 1m mg g) ) D DR RG G p pa ay ym me en nt t•• R Re eiim mb bu ur rs se ed d a at t 8 80 0% % o of f 9 95 5% %•• R Re eiim mb bu ur rs se ed d a at t 8 80 0% % o of f 9 95 5% % o of f A AW WP P o of f A AW WP P C Co om mm me er rc ciia all C Co om mm me er rc ciia all C Co om mm me er rc ciia all •• U Us se e J J3 34 49 90 0•• U Us se e J J3 34 49 90 0 u un nt tiill 1 10 0/ /1 1/ /2 20 02 20 0•• U Us se e J J3 34 49 90 0 u un nt tiill 1 10 0/ /1 1/ /2 20 02 20 0 •• B Bu un nd dlle ed d a an nd d p pa ar rt t o of f a a•• M Ma ay y b be e b bu un nd dlle ed d w wiit th h •• M Ma ay y b be e b bu un nd dlle ed d w wiit th h c ca as se e r ra at te e p pr ro oc ce ed du ur re e o or r s se ep pa ar ra at te elly y p pr ro oc ce ed du ur re e o or r s se ep pa ar ra at te elly y r re eiim mb bu ur rs se ed d b ba as se ed d o on n t th he e r re eiim mb bu ur rs se ed d b ba as se ed d o on n t th he e f fa ac ciilliit ty y c co on nt tr ra ac ct t f fa ac ciilliit ty y c co on nt tr ra ac ct t AWP=average wholesale price; DRG=diagnosis related group. Permanent J-code J1738 Injection, meloxicam, 1 mg“ effective 10/1/2020 and will replace all other codes 20 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comSurgical Setting Coding and Reimbursement Hospital Inpatient Hospital Outpatient Ambulatory Surgery Centers M Me ed diic ca ar re e M Me ed diic ca ar re e M Me ed diic ca ar re e •• U Us se e J J3 34 49 90 0•• U Un niiq qu ue e C Co od de e, , C C9 90 05 59 9 •• U Un niiq qu ue e C Co od de e, , C C9 90 05 59 9 •• R Re eiim mb bu ur rs se em me en nt t b bu un nd dlle ed d iin nt to o ( (IIn nj je ec ct tiio on n, , M Me ello ox xiic ca am m 1 1m mg g) ) ( (IIn nj je ec ct tiio on n, , M Me ello ox xiic ca am m 1 1m mg g) ) D DR RG G p pa ay ym me en nt t•• R Re eiim mb bu ur rs se ed d a at t 8 80 0% % o of f 9 95 5% %•• R Re eiim mb bu ur rs se ed d a at t 8 80 0% % o of f 9 95 5% % o of f A AW WP P o of f A AW WP P C Co om mm me er rc ciia all C Co om mm me er rc ciia all C Co om mm me er rc ciia all •• U Us se e J J3 34 49 90 0•• U Us se e J J3 34 49 90 0 u un nt tiill 1 10 0/ /1 1/ /2 20 02 20 0•• U Us se e J J3 34 49 90 0 u un nt tiill 1 10 0/ /1 1/ /2 20 02 20 0 •• B Bu un nd dlle ed d a an nd d p pa ar rt t o of f a a•• M Ma ay y b be e b bu un nd dlle ed d w wiit th h •• M Ma ay y b be e b bu un nd dlle ed d w wiit th h c ca as se e r ra at te e p pr ro oc ce ed du ur re e o or r s se ep pa ar ra at te elly y p pr ro oc ce ed du ur re e o or r s se ep pa ar ra at te elly y r re eiim mb bu ur rs se ed d b ba as se ed d o on n t th he e r re eiim mb bu ur rs se ed d b ba as se ed d o on n t th he e f fa ac ciilliit ty y c co on nt tr ra ac ct t f fa ac ciilliit ty y c co on nt tr ra ac ct t AWP=average wholesale price; DRG=diagnosis related group. Permanent J-code J1738 Injection, meloxicam, 1 mg“ effective 10/1/2020 and will replace all other codes 20 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Pass-Through, Unique C-code & J-code All Granted by CMS Unique C-Code Granted & Currently Effective Granted, 3 years of pass-through coverage until June 30, 2023 March 2020 July 1, 2020 March 1, 2020 Unique Code, C9059 (Injection, Meloxicam 1mg) Effective July 1, 2020 Apply for unique C-code Permanent J-Code Granted Pass-through continues until June 30, 2023 July/August 2020 October 1, 2020 July 2020 Level II HCPCS code J1738 Injection, meloxicam, 1 mg“ effective 10/1/2020 CMS posts J-code replaces unique C-code when it becomes effective; final decision Pass-through continues until June 30, 2023 Source: Centers for Medicare & Medicaid Services (CMS) updated its Healthcare Common Procedural Coding System (HCPCS) Level II coding procedures in November 2019 to enable shorter and more frequent HCPCS code application cycles. More information can be found at https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo 21 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comPass-Through, Unique C-code & J-code All Granted by CMS Unique C-Code Granted & Currently Effective Granted, 3 years of pass-through coverage until June 30, 2023 March 2020 July 1, 2020 March 1, 2020 Unique Code, C9059 (Injection, Meloxicam 1mg) Effective July 1, 2020 Apply for unique C-code Permanent J-Code Granted Pass-through continues until June 30, 2023 July/August 2020 October 1, 2020 July 2020 Level II HCPCS code J1738 Injection, meloxicam, 1 mg“ effective 10/1/2020 CMS posts J-code replaces unique C-code when it becomes effective; final decision Pass-through continues until June 30, 2023 Source: Centers for Medicare & Medicaid Services (CMS) updated its Healthcare Common Procedural Coding System (HCPCS) Level II coding procedures in November 2019 to enable shorter and more frequent HCPCS code application cycles. More information can be found at https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo 21 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


ANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Demonstrated COX-2 Preferential Once-daily IV Up to 24-hour Safety & Tolerability IV NSAID* push pain relief Efficacy in That can be Ready-to-use, no Evaluated in more orthopedic & soft incorporated into reconstitution or 1 than 1400 patients tissue procedures MMA protocols refrigeration 1. Data on file. Baudax Bio, Inc. *The mechanism of action of IV meloxicam, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-1 = cyclooxygenase 1; COX-2 = cyclooxygenase 2; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; MMA = multimodal analgesia 22 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comANJESO® (meloxicam) Injection: The First and Only Once-Daily IV Analgesic Demonstrated COX-2 Preferential Once-daily IV Up to 24-hour Safety & Tolerability IV NSAID* push pain relief Efficacy in That can be Ready-to-use, no Evaluated in more orthopedic & soft incorporated into reconstitution or 1 than 1400 patients tissue procedures MMA protocols refrigeration 1. Data on file. Baudax Bio, Inc. *The mechanism of action of IV meloxicam, like other NSAIDs, is not completely understood, but involves inhibition of both COX-1 and COX-2 pathways. COX-1 = cyclooxygenase 1; COX-2 = cyclooxygenase 2; IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug; MMA = multimodal analgesia 22 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Company Highlights • ANJESO® (meloxicam) injection* – Product launched June 2020 – Approved February 20, 2020 for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics – Significant Potential Commercial Opportunity • Additional pipeline candidates in clinical stage development for acute care settings • Baudax Cash position – $39.4 million as of June 30, 2020 – $50 million credit facility secured in May 2020; $10 million drawn – Short dated Cash Exercisable Series B Warrants expected to provide additional $25 million in gross proceeds before or by April 2021, assuming full exercise. As of June 30, 2020, warrant exercises have provided $2.5 million in net proceeds. • Experienced management team with significant commercial, development, and regulatory experience * Limitation of Use: Because of delayed onset of analgesia, ANJESO® alone is not recommended for use when rapid onset of analgesia is required. 23 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.comCompany Highlights • ANJESO® (meloxicam) injection* – Product launched June 2020 – Approved February 20, 2020 for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics – Significant Potential Commercial Opportunity • Additional pipeline candidates in clinical stage development for acute care settings • Baudax Cash position – $39.4 million as of June 30, 2020 – $50 million credit facility secured in May 2020; $10 million drawn – Short dated Cash Exercisable Series B Warrants expected to provide additional $25 million in gross proceeds before or by April 2021, assuming full exercise. As of June 30, 2020, warrant exercises have provided $2.5 million in net proceeds. • Experienced management team with significant commercial, development, and regulatory experience * Limitation of Use: Because of delayed onset of analgesia, ANJESO® alone is not recommended for use when rapid onset of analgesia is required. 23 Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.ANJESO.com


Important Safety Information 24Important Safety Information 24


Indication and Boxed Warning INDICATION ANJESO is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use: Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk • Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. • ANJESO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. 25Indication and Boxed Warning INDICATION ANJESO is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use: Because of delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk • Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. • ANJESO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. 25


Important Safety Information (cont) CONTRAINDICATIONS ANJESO is contraindicated in patients with: • Known hypersensitivity (eg, anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product. • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. • In the setting of coronary artery bypass graft (CABG) surgery. • Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion. WARNINGS AND PRECAUTIONS Hepatotoxicity: Elevations of ALT or AST have been reported in patients with NSAIDs. In addition, rare, sometimes fatal, cases of severe hepatic injury including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue ANJESO immediately if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. Hypertension: NSAIDs including ANJESO can lead to new onset of hypertension or worsening of preexisting hypertension, which may contribute to the increased incidence of cardiovascular (CV) events. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. Heart Failure and Edema: NSAID use increased the risk of myocardial infarction (MI), hospitalization for heart failure, and death. Avoid use of ANJESO in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. If ANJESO is used in patients with severe heart failure, monitor patients for signs of worsening heart failure. 26Important Safety Information (cont) CONTRAINDICATIONS ANJESO is contraindicated in patients with: • Known hypersensitivity (eg, anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product. • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. • In the setting of coronary artery bypass graft (CABG) surgery. • Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion. WARNINGS AND PRECAUTIONS Hepatotoxicity: Elevations of ALT or AST have been reported in patients with NSAIDs. In addition, rare, sometimes fatal, cases of severe hepatic injury including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue ANJESO immediately if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. Hypertension: NSAIDs including ANJESO can lead to new onset of hypertension or worsening of preexisting hypertension, which may contribute to the increased incidence of cardiovascular (CV) events. Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure. Heart Failure and Edema: NSAID use increased the risk of myocardial infarction (MI), hospitalization for heart failure, and death. Avoid use of ANJESO in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure. If ANJESO is used in patients with severe heart failure, monitor patients for signs of worsening heart failure. 26


Important Safety Information (cont) Post MI Patients: Avoid the use of ANJESO in patients with recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ANJESO is used in these patients, monitor for signs of cardiac ischemia. Renal Toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. ANJESO is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency who are at risk for renal failure due to volume depletion. Correct volume status in dehydrated or hypovolemic patients prior to initiating ANJESO. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ANJESO in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. If ANJESO is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. Anaphylactic Reactions: Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma. Seek emergency help if an anaphylactic reaction occurs. Exacerbation of Asthma Related to Aspirin Sensitivity: ANJESO is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity). Serious Skin Reactions: NSAIDs, including ANJESO, can cause serious skin reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and can occur without warning. Discontinue ANJESO at first appearance of skin rash or other signs of hypersensitivity. Hematologic Toxicity: Anemia has occurred in NSAID-treated patients. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. NSAIDs, including ANJESO, may increase the risk of bleeding events. Monitor patients for signs of bleeding. 27Important Safety Information (cont) Post MI Patients: Avoid the use of ANJESO in patients with recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ANJESO is used in these patients, monitor for signs of cardiac ischemia. Renal Toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injury. ANJESO is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency who are at risk for renal failure due to volume depletion. Correct volume status in dehydrated or hypovolemic patients prior to initiating ANJESO. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of ANJESO in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function. If ANJESO is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. Anaphylactic Reactions: Meloxicam has been associated with anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma. Seek emergency help if an anaphylactic reaction occurs. Exacerbation of Asthma Related to Aspirin Sensitivity: ANJESO is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity). Serious Skin Reactions: NSAIDs, including ANJESO, can cause serious skin reactions, including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal and can occur without warning. Discontinue ANJESO at first appearance of skin rash or other signs of hypersensitivity. Hematologic Toxicity: Anemia has occurred in NSAID-treated patients. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. NSAIDs, including ANJESO, may increase the risk of bleeding events. Monitor patients for signs of bleeding. 27


Important Safety Information (cont) DRUG INTERACTIONS Drugs That Interfere With Hemostasis (eg, warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking ANJESO with drugs that interfere with hemostasis. Concomitant use of ANJESO and analgesic doses of aspirin is not generally recommended. Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with ANJESO may diminish the antihypertensive effect of these drugs. Monitor blood pressure. ACE Inhibitors and ARBs: Concomitant use with ANJESO in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function. Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to ensure diuretic efficacy including antihypertensive effects. ADVERSE REACTIONS The most common adverse reactions in controlled clinical trials occurring in ≥2% of patients treated with ANJESO and at a greater frequency than placebo included: constipation, gamma-glutamyl transferase increased and anemia. USE IN SPECIFIC POPULATIONS Pregnancy: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation. Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of ANJESO in women who have trouble conceiving. Please see full Prescribing Information, including Boxed Warning, at www.baudaxbio.com. 28Important Safety Information (cont) DRUG INTERACTIONS Drugs That Interfere With Hemostasis (eg, warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking ANJESO with drugs that interfere with hemostasis. Concomitant use of ANJESO and analgesic doses of aspirin is not generally recommended. Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with ANJESO may diminish the antihypertensive effect of these drugs. Monitor blood pressure. ACE Inhibitors and ARBs: Concomitant use with ANJESO in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function. Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to ensure diuretic efficacy including antihypertensive effects. ADVERSE REACTIONS The most common adverse reactions in controlled clinical trials occurring in ≥2% of patients treated with ANJESO and at a greater frequency than placebo included: constipation, gamma-glutamyl transferase increased and anemia. USE IN SPECIFIC POPULATIONS Pregnancy: Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant women starting at 30 weeks gestation. Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of ANJESO in women who have trouble conceiving. Please see full Prescribing Information, including Boxed Warning, at www.baudaxbio.com. 28


September 2020 29September 2020 29